Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials updateSep 25Weekly roundup, 6 itemsabemaciclibbrenipatide
Lilly raises 2026 revenue guidance to $85-87 billion on Mounjaro, Zepbound growthAug 5Quarterly updateEli Lillytirzepatide
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial startsAug 3Quarterly updateCRISPR Therapeutics AGCTX340
Nurix strikes $2.3 billion Roche pact for BTK degrader bexobrutidegJul 9Quarterly updatebexobrutidegNurix Therapeutics, Inc.
Sign inSign in